BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-07-28 15:35 |
UPDATE ON BEMCENTINIB'S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC
|
English | 5.0 KB | ||
| 2020-07-20 05:00 |
BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR …
|
English | 228.6 KB | ||
| 2020-07-20 05:00 |
BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR …
|
English | 7.7 KB | ||
| 2020-07-16 08:10 |
BerGenBio ASA: Registered share capital increase
|
English | 221.7 KB | ||
| 2020-07-16 08:10 |
BerGenBio ASA: Registered share capital increase
|
English | 7.6 KB | ||
| 2020-07-08 15:03 |
BerGenBio announces amendment to the ACCORD clinical trial protocol for BEMCENT…
|
English | 223.2 KB | ||
| 2020-07-08 15:03 |
BerGenBio announces amendment to the ACCORD clinical trial protocol for BEMCENT…
|
English | 4.8 KB | ||
| 2020-07-07 05:00 |
BerGenBio to present at Digital Novel Coronavirus Investment Forum
|
English | 226.5 KB | ||
| 2020-07-07 05:00 |
BerGenBio to present at Digital Novel Coronavirus Investment Forum
|
English | 4.8 KB | ||
| 2020-07-06 14:41 |
BerGenBio ASA: Primary Insider notification
|
English | 667 bytes | ||
| 2020-07-06 14:35 |
BerGenBio ASA: Final results of the subsequent offering
|
English | 223.6 KB | ||
| 2020-07-06 14:35 |
BerGenBio ASA: Final results of the subsequent offering
|
English | 8.6 KB | ||
| 2020-07-03 18:57 |
BerGenBio ASA: Results of the subsequent offering
|
English | 223.2 KB | ||
| 2020-07-03 18:57 |
BerGenBio ASA: Results of the subsequent offering
|
English | 8.2 KB | ||
| 2020-07-03 14:35 |
BerGenBio ASA: Primary Insider notification
|
English | 669 bytes |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
